NCT01231555 - Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2010

Primary Completion Date

July 4, 2011

Study Completion Date

July 4, 2011

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK2248761 100 mg once daily

1x100 mg capsule plus matching placebo

DRUG

GSK2248761 200 mg once daily

2x100 mg capsules

DRUG

Efavirenz 600 mg once daily

1x600mg tablet

Trial Locations (12)

GSK Investigational Site, Berlin

GSK Investigational Site, Hamburg

GSK Investigational Site, Hamburg

GSK Investigational Site, Marid

GSK Investigational Site, Hanover

GSK Investigational Site, Montpellier

GSK Investigational Site, Frankfurt am Main

GSK Investigational Site, Paris

GSK Investigational Site, Levallois-Perret

GSK Investigational Site, Nice

GSK Investigational Site, Badalona

GSK Investigational Site, Barcelona